Back to Journals » Journal of Hepatocellular Carcinoma » Volume 8

Review

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario

       
Total article views   HTML views PDF downloads Totals
14,163 Dovepress* 7,721+ 1,106 8,827
PubMed Central* 6,442 882 7,324
Totals 14,163 1,988 16,151
*Since 15 April 2021
Total mentioned Facebook Delicious Reddit Twitter Others
10 0 0 0 5 5

View citations on PubMed Central and Google Scholar